Chun-Hou Liao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5908197/publications.pdf

Version: 2024-02-01

840119 794141 19 476 11 19 citations h-index g-index papers 19 19 19 456 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Adverse Events of Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor Overactivity: Risk Factors and Influence on Treatment Outcome. European Urology, 2010, 58, 919-926.	0.9	113
2	Increased Risk of Large Post-Void Residual Urine and Decreased Long-Term Success Rate After Intravesical OnabotulinumtoxinA Injection for Refractory Idiopathic Detrusor Overactivity. Journal of Urology, 2013, 189, 1804-1810.	0.2	76
3	Optimizing a Male Reproductive Aging Mouse Model by d-Galactose Injection. International Journal of Molecular Sciences, 2016, 17, 98.	1.8	42
4	Significant association between serum dihydrotestosterone level and prostate volume among Taiwanese men aged 40–79 years. Aging Male, 2012, 15, 28-33.	0.9	33
5	Current and potential urological applications of botulinum toxin A. Nature Reviews Urology, 2015, 12, 519-533.	1.9	31
6	Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection on Elderly Patients with Chronic Central Nervous System Lesions and Overactive Bladder. PLoS ONE, 2014, 9, e105989.	1.1	30
7	Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxina injection in patients with refractory detrusor overactivity. Neurourology and Urodynamics, 2014, 33, 1235-1239.	0.8	29
8	Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study. Neurourology and Urodynamics, 2016, 35, 717-723.	0.8	24
9	Mirabegron 25 mg Monotherapy Is Safe but Less Effective in Male Patients With Overactive Bladder and Bladder Outlet Obstruction. Urology, 2018, 117, 115-119.	0.5	18
10	Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome. International Neurourology Journal, 2015, 19, 213-219.	0.5	16
11	High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment. Medicine (United States), 2016, 95, e4962.	0.4	15
12	Perspectives on mirabegron in the treatment of overactive bladder syndrome: A new beta-3 adrenoceptor agonist. Urological Science, 2015, 26, 17-23.	0.2	10
13	Significant intravesical prostatic protrusion and prostatic calcification predict unfavorable outcomes of medical treatment for male lower urinary tract symptoms. Urological Science, 2016, 27, 13-16.	0.2	8
14	Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation?. Toxins, 2019, 11, 547.	1.5	8
15	Body mass index and buttock circumference are independent predictors of disintegration failure in extracorporeal shock wave lithotripsy for ureteral calculi. Journal of the Formosan Medical Association, 2013, 112, 421-425.	0.8	6
16	Current consensus and controversy on the treatment of male lower urinary tract symptoms/benign prostatic hyperplasia. Tzu Chi Medical Journal, 2017, 29, 1.	0.4	6
17	Mirabegron escalation to $50 \hat{A}$ mg further improves daily urgency and urgency urinary incontinence in Asian patients with overactive bladder. Journal of the Formosan Medical Association, 2019, 118, 700-706.	0.8	4
18	Selfâ€perception of symptoms, medical help seeking, and selfâ€help strategies of women with interstitial cystitis/painful bladder syndrome. LUTS: Lower Urinary Tract Symptoms, 2020, 12, 183-189.	0.6	4

#	Article	IF	CITATIONS
19	The efficacy of extracorporeal shockwave lithotripsy for symptomatic ureteral stones: Predictors of treatment failure without the assistance of computed tomography. PLoS ONE, 2017, 12, e0184855.	1.1	3